Project Details
Projekt Print View

NAFLD-NASH-HCC progression: mechanisms of stage-transitions and identification of time windows for prevention

Subject Area Gastroenterology
Term from 2021 to 2024
Project identifier Deutsche Forschungsgemeinschaft (DFG) - Project number 457840828
 
Final Report Year 2024

Final Report Abstract

Metabolic dysfunction associated fatty liver disease (MAFLD) is the most common chronic liver disease in Western countries, which may progress to steatohepatitis (MASH) and eventually to cirrhosis and hepatocellular carcinoma (HCC). Because of poor understanding of the driving molecular mechanisms the current therapeutic options are limited. In this project we have established a mouse model that recapitulates MAFLD progression as in human patients. Key results include: (1) identification of the key events in MAFLD progression; (2) discovery of “Zombie cells” as drivers of tissue inflammation and carcinogenesis; (3) Impaired glyoxylate detoxification in MAFLD as a risk factor for hyperoxaluria; (4) Identification of macropinocytosis as a key event in MAFLD progression and therapeutic interventions; (5) Inhibition of the renal ASBT as a possible therapeutic target in cholemic nephropathy; and (6) targeting ductular reaction prevents disease progression. Translation relevance of these findings was tested in blood as well as tissue samples of patients with MAFLD.

Publications

 
 

Additional Information

Textvergrößerung und Kontrastanpassung